Terray Therapeutics

Rounds and research, on one timeline

1. 2026-10-15
   Research

   Level 2 · Computed

   Terray and NVIDIA fine-tune a Nemotron model to read chemical reaction diagrams, setting a new best on the RxnCaption benchmark

   Synthesis planners like Terray's own TerraSynth need training data drawn from how chemists actually describe routes, and most of that sits locked in diagram form in papers. A model that parses those diagrams turns the literature into structured reaction data a planner can learn from, and lets an agent read a chemical document on the fly. The gain over the prior best is modest (about four F1 points), but it is on a public benchmark scored with the original authors' code.

   Timeline entry →terraytx.ai ↗

2. 2026-06-11
   Research

   Level 4 · Tested in the physical world

   Terray's TerraSynth designs molecules with a route to make them, and in Terray's own projects chemists made half its compounds in 4 weeks instead of 8

   Making a molecule is the slowest step in drug design, and AI designs often stall there. This is the company's own post, not a paper: the project comparison is before and after a date cutoff, not randomised, over 244 compounds, and the check that designs stay potent used Terray's own model, not an assay.

   Timeline entry →terraytx.ai ↗

3. 2026-02-08
   Research

   Level 2 · Computed

   Terray's TerraBind, a coarse-structure model, beats Boltz-2 by about 20% on binding-affinity correlation and runs 26x faster

   Screening millions of molecules needs a cheap model. These are software scores, and the 18-assay set is proprietary, so nobody outside can rerun it.

   Timeline entry →arxiv.org ↗

4. 2024-10Series B
   Round

   $120M

   For: take internal programs into clinical trials; improve tNova

   Toward the clinicModels and platform

   Total equity since inception over $200M.

   Co-lead · Bedford Ridge CapitalCo-lead · NVentures (NVIDIA) ✓Maverick CapitalGoldcrest CapitalMadrona Ventures ✓Two Sigma Ventures ✓XTX VenturesDigitalis Ventures ✓Alexandria Venture Investments

   On the deal: Kimberly Powell (VP of Healthcare, NVentures (NVIDIA)); Sid Shenai (Investor, alongside Bedford Ridge Capital, Bedford Ridge Capital, joins the board)

   The investor's own page says · Madrona Ventures: Initial Investment 2020

   Announced by the company · biospace.com ↗

5. 2022-02-15Series A
   Round

   $60M

   For: advance the tNova platform

   Models and platform

   Lead · Madrona Venture Group ✓Two Sigma Ventures ✓Digitalis Ventures ✓KdT VenturesGoldcrest CapitalXTX VenturesAlexandria Venture InvestmentsSahsen VenturesGreentrail Capital

   On the deal: Chris Picardo (Partner, Madrona Venture Group); Dusan Perovic (Partner, Two Sigma Ventures); Geoffrey W. Smith (Managing Partner, Digitalis Ventures)

   Announced by the company · terraytx.ai ↗

6. 2022-02-15date disclosed · close date not givenSeed
   Round

   $20M

   Not stated

   First disclosed in the Series A announcement as previously unannounced; its date was not given.

   Co-lead · Digitalis Ventures ✓Co-lead · Two Sigma Ventures ✓

   Announced by the company · terraytx.ai ↗

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →